Each cancer consists of a diverse mix of cells. Each person’s immune system generates an individualized response against each specific cancer cell type. This results in extreme variabilities of interactions between people’s immune systems and their cancers. Delivering a cancer vaccine that stimulates the immune system to kill cancer cells (and only cancer cells) requires a broad and deep understanding of immunology.


In order to create such vaccines, we have created our proprietary databases by building a comprehensive taxonomy of immunological information linking genetics to cancer cell characteristics and proprietary algorithms to analyze billions of genes and compute patients’ immune responses against their specific types of cancer. We continually use the latest published scientific knowledge and proprietary learnings to update our databases and further refine our algorithms. Our ongoing quality control ensures data integrity and reliability.

TREOS’ algorithms and databases are at the heart of the Precision Therapeutic Cancer Vaccine Technology that we use to create our PolyPEPI™ Immunotherapy Cancer Vaccine Family and PolyPEPI™ Companion Diagnostics. Each PolyPEPI™ vaccine is designed to induce optimized immune responses to kill a broad range of cancer cells without attacking healthy cells. Each PolyPEPI™ vaccine is accompanied by a companion diagnostic test (CDx) that characterizes each patient’s immune responses against specific cancer cell types and identifies those patients likely to benefit from the vaccine. Our computer simulated (in silico) trials use our proprietary algorythm and databases to predict the benefit/risk profile of our vaccines and the proportion of patients with likely clinical benefit.